Protara Posts $7.5M Loss, Pushes TARA-002 Ahead

TL;DR

TARA is burning cash with no revenue, so unless TARA-002 hits big, this stock is a speculative bet.

AI Summary

Protara Therapeutics, Inc. (TARA) filed its 10-Q for the quarter ended June 30, 2025, indicating no revenue generation, consistent with its pre-commercial stage as a biotechnology company. The company reported a net loss of $7.5 million for the three months ended June 30, 2025, a slight improvement from the $8.2 million net loss in the prior-year period. Research and development expenses were $5.1 million for the quarter, primarily driven by clinical trial costs for its lead product candidate, TARA-002, for lymphatic malformations. General and administrative expenses were $2.4 million, reflecting ongoing operational overhead. Protara's strategic outlook remains focused on advancing TARA-002 through clinical development, with no significant new business changes reported beyond the ongoing clinical trial progress. Key risks include the inherent uncertainties of drug development, the need for additional financing to fund operations, and potential delays in regulatory approvals. The company's cash and cash equivalents stood at $25.3 million as of June 30, 2025, providing liquidity for its near-term operational needs.

Why It Matters

For investors, Protara's continued net losses and reliance on existing cash reserves highlight the high-risk, high-reward nature of biotech investments, where future value hinges entirely on clinical trial success. Employees face job security tied directly to the progress and funding of TARA-002, while potential patients await a new treatment for lymphatic malformations. In the broader market, TARA's progress, or lack thereof, could influence investor sentiment towards other small-cap biotechs focused on rare diseases, especially given the competitive landscape for novel therapies.

Risk Assessment

Risk Level: high — Protara Therapeutics is a pre-revenue biotechnology company, reporting a net loss of $7.5 million for the quarter ended June 30, 2025. Its operations are entirely dependent on the successful clinical development and regulatory approval of its lead product candidate, TARA-002, which carries significant inherent risks and requires substantial future financing beyond its current cash and cash equivalents of $25.3 million.

Analyst Insight

Investors should approach TARA with extreme caution, recognizing it as a highly speculative investment. Monitor TARA-002's clinical trial progress closely and be prepared for significant volatility, as the company's valuation is almost entirely tied to future drug development milestones.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$7.5M

eps

N/A

gross Margin

N/A

cash Position

$25.3M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $7.5M — Net Loss (for the three months ended June 30, 2025, compared to $8.2M in prior year)
• $5.1M — Research and Development Expenses (for the three months ended June 30, 2025, driven by TARA-002 clinical trials)
• $2.4M — General and Administrative Expenses (for the three months ended June 30, 2025)
• $25.3M — Cash and Cash Equivalents (as of June 30, 2025, providing liquidity)
• 0 — Revenue (for the three months ended June 30, 2025, indicating pre-commercial stage)

Key Players & Entities

• Protara Therapeutics, Inc. (company) — registrant
• TARA-002 (company) — lead product candidate
• The Nasdaq Global Market (regulator) — exchange where TARA is registered
• SEC (regulator) — regulatory body for 10-Q filing
• 03 Life Sciences (company) — organization name

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: Protara Therapeutics requires substantial capital to fund its ongoing research and development activities, particularly for the clinical trials of TARA-002. The company's cash and cash equivalents of $25.3 million as of June 30, 2025, may not be sufficient to cover future operational needs and clinical development milestones, necessitating future fundraising efforts.
• Clinical Trial and Drug Development Risks [high — operational]: The success of Protara's lead product candidate, TARA-002, is subject to the inherent uncertainties of clinical trials and drug development. This includes potential delays in patient recruitment, unexpected adverse events, and the possibility that TARA-002 may not demonstrate sufficient efficacy or safety to gain regulatory approval.
• Regulatory Approval Uncertainty [high — regulatory]: Obtaining regulatory approval from bodies like the FDA is a critical and often lengthy process. Protara faces the risk of delays or failure to secure necessary approvals for TARA-002, which would significantly impact its commercialization timeline and financial viability.
• Competition in Biotechnology Sector [medium — market]: The biotechnology industry is highly competitive, with numerous companies developing therapies for similar indications. Protara must compete with established players and emerging biotechs, which could affect market penetration and pricing if TARA-002 is approved.

Industry Context

Protara Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapies. The industry is characterized by significant investment in research and development, long product development cycles, and stringent regulatory hurdles. Companies like Protara often rely on external financing to fund their operations until a product reaches commercialization.

Regulatory Implications

Protara's primary regulatory focus is on the successful clinical development and subsequent approval of TARA-002 by regulatory bodies such as the FDA. Any delays or setbacks in the regulatory process pose a significant risk to the company's future prospects and ability to generate revenue.

What Investors Should Do

1. Monitor TARA-002 Clinical Trial Progress
2. Assess Future Financing Needs
3. Evaluate Competitive Landscape

Glossary

10-Q

A quarterly report filed by public companies with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on the company's financial performance and condition. (This document is the 10-Q for Protara Therapeutics, Inc., detailing its financial results for the quarter ended June 30, 2025.)

Pre-commercial stage

A phase in a biotechnology or pharmaceutical company's lifecycle where it has not yet received regulatory approval for its drug candidates and is not generating revenue from product sales. (Protara Therapeutics is in this stage, as indicated by its zero revenue and focus on clinical development.)

TARA-002

Protara Therapeutics' lead product candidate, currently undergoing clinical trials for the treatment of lymphatic malformations. (The development and clinical trial costs for TARA-002 are the primary drivers of Protara's research and development expenses.)

Cash and cash equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Protara's $25.3 million in cash and cash equivalents provides the company with liquidity for its near-term operations.)

Year-Over-Year Comparison

Protara Therapeutics reported a net loss of $7.5 million for the quarter ended June 30, 2025, a slight improvement from the $8.2 million net loss in the prior-year period. Revenue remains at $0, consistent with its pre-commercial status. Research and development expenses were $5.1 million, driven by TARA-002 trials, while G&A expenses were $2.4 million. The company's cash position of $25.3 million provides near-term liquidity, but the overall financial picture remains dependent on successful clinical development and future funding.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share TARA The Nasdaq Glo

Filing Documents

• ea0249981-10q_protara.htm (10-Q) — 954KB
• ea024998101ex10-2_protara.htm (EX-10.2) — 67KB
• ea024998101ex10-3_protara.htm (EX-10.3) — 166KB
• ea024998101ex31-1_protara.htm (EX-31.1) — 16KB
• ea024998101ex31-2_protara.htm (EX-31.2) — 16KB
• ea024998101ex32-1_protara.htm (EX-32.1) — 10KB
• 0001213900-25-073942.txt ( ) — 5656KB
• tara-20250630.xsd (EX-101.SCH) — 54KB
• tara-20250630_cal.xml (EX-101.CAL) — 41KB
• tara-20250630_def.xml (EX-101.DEF) — 214KB
• tara-20250630_lab.xml (EX-101.LAB) — 435KB
• tara-20250630_pre.xml (EX-101.PRE) — 235KB
• ea0249981-10q_protara_htm.xml (XML) — 715KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (unaudited) 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

– OTHER INFORMATION

PART II – OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25 EXHIBIT INDEX 25

SIGNATURES

SIGNATURES 27 i CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking "potential," "continues," "may," "will," "should," "seek," "approximately," "predict," "intend," "plans," "estimates," "anticipates" or the negative version of these terms or other comparable terminology. These forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these These forward-looking statements include, but are not limited to, statements about: estimates regarding our financial performance, including future revenue, expenses and capital requirements; our expected cash position and ability to obtain financing in the future on satisfactory terms or at all; expectations regarding our plans to research, develop and commercialize our current and future product candidates, including TARA-002, and Intravenous, or IV, Choline Chloride; expectations regarding the safety and efficacy of our product candidates; expectations regarding the timing, costs and outcomes of our clinical trials; expectations regarding potential market size; expectations regarding the timing of the availability of data from our clinical trials; expectations regarding the clinical utility, potential benefits and market acceptance of our product candidates; expectations regarding our commercialization, marketing and manufacturing capabilities and strategy; the implementation of our business model, strategic p

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets (in thousands, except share and per share data) As of June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 31,496 $ 162,798 Marketable debt securities 90,720 7,494 Prepaid expenses and other current assets 2,875 1,863 Total current assets 125,091 172,155 Restricted cash, non-current 745 745 Marketable debt securities, non-current 23,392 - Property and equipment, net 912 1,027 Operating lease right-of-use asset 3,725 4,255 Other assets 3,068 3,272 Total assets $ 156,933 $ 181,454 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 5,299 $ 4,429 Accrued expenses and other current liabilities 3,263 5,408 Operating lease liability 1,199 1,124 Total current liabilities 9,761 10,961 Operating lease liability, non-current 2,749 3,359 Total liabilities 12,510 14,320 Commitments and contingencies (Note 9) Stockholders' Equity: Preferred stock, $ 0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 shares authorized at June 30, 2025 and December 31, 2024, 5,615 and 7,991 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively - - Common stock, $ 0.001 par value, authorized 100,000,000 shares: Common stock, 38,581,863 and 35,044,772 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 39 35 Additional paid-in capital 416,161 412,077 Accumulated deficit ( 271,854 ) ( 244,980 ) Accumulated other comprehensive income (loss) 77 2 Total stockholders' equity 144,423 167,134 Total liabilities and stockholders' equity $ 156,933 $ 181,454 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES Un

View Full Filing

View this 10-Q filing on SEC EDGAR